Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy

Yi Wei Chung, Yao Hsu Yang, Cho Kai Wu, Chih Chieh Yu, Jyh Ming Jimmy Juang, Yi Chih Wang, Chia Ti Tsai, Lian Yu Lin, Ling Ping Lai, Juey Jen Hwang, Fu Tien Chiang, Pau Chung Chen, Jiunn Lee Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear. Methods: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute. All dialysis patients aged 18 or older without history of AF before ESRD were incorporated. A total of 113,191 dialysis patients were enrolled in the study. The median follow-up time was 4.17 years. We collected information on prescribed drug dosage, number of days of treatment and the total number of pills dispensed from the outpatient pharmacy prescription database. All individuals in the study cohort with the first occurrence of AF were included as cases. Results: In spironolactone group, the incidence of developing new AF was significantly lower than that in the control group both before (0.8% vs. 3.3%, P = 0.019) and after PS matching (1.2% vs. 3.0%, P = 0.019). Before PS matching, Cox's proportional hazard regression analyses showed that spironolactone was associated with 60% reduction of new AF (HR = 0.372 [0.200-0.692], P = 0.002) and the protective effect is dose-responsive in accumulated dose, treatment duration and mean daily dose. After PS matching, the overall AF prevention effect remained significant (HR = 0.400 [0.179-0.895], P = 0.026) while the dose-response relationship became borderline significant. Subgroup analyses showed that the protective effect was more evident in some specific subgroup patients. Conclusion: Our study showed that spironolactone therapy was associated with lower risk of developing AF in a dose-responsive manner in patients with dialysis. Further randomized study is needed to confirm this observation.

Original languageEnglish
Pages (from-to)962-966
Number of pages5
JournalInternational Journal of Cardiology
Volume202
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Spironolactone
Renal Replacement Therapy
Atrial Fibrillation
Dialysis
Catastrophic Illness
Databases
Therapeutics
Chronic Kidney Failure
Prescriptions
Registries
Cohort Studies
Outpatients
Regression Analysis
Control Groups
Incidence
Health
Pharmaceutical Preparations

Keywords

  • Atrial fibrillation
  • ESRD
  • Hemodialysis
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. / Chung, Yi Wei; Yang, Yao Hsu; Wu, Cho Kai; Yu, Chih Chieh; Juang, Jyh Ming Jimmy; Wang, Yi Chih; Tsai, Chia Ti; Lin, Lian Yu; Lai, Ling Ping; Hwang, Juey Jen; Chiang, Fu Tien; Chen, Pau Chung; Lin, Jiunn Lee.

In: International Journal of Cardiology, Vol. 202, 01.01.2016, p. 962-966.

Research output: Contribution to journalArticle

Chung, Yi Wei ; Yang, Yao Hsu ; Wu, Cho Kai ; Yu, Chih Chieh ; Juang, Jyh Ming Jimmy ; Wang, Yi Chih ; Tsai, Chia Ti ; Lin, Lian Yu ; Lai, Ling Ping ; Hwang, Juey Jen ; Chiang, Fu Tien ; Chen, Pau Chung ; Lin, Jiunn Lee. / Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. In: International Journal of Cardiology. 2016 ; Vol. 202. pp. 962-966.
@article{9f12e032cea44b1e8fecbe0d4566ad07,
title = "Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy",
abstract = "Objectives: Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear. Methods: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute. All dialysis patients aged 18 or older without history of AF before ESRD were incorporated. A total of 113,191 dialysis patients were enrolled in the study. The median follow-up time was 4.17 years. We collected information on prescribed drug dosage, number of days of treatment and the total number of pills dispensed from the outpatient pharmacy prescription database. All individuals in the study cohort with the first occurrence of AF were included as cases. Results: In spironolactone group, the incidence of developing new AF was significantly lower than that in the control group both before (0.8{\%} vs. 3.3{\%}, P = 0.019) and after PS matching (1.2{\%} vs. 3.0{\%}, P = 0.019). Before PS matching, Cox's proportional hazard regression analyses showed that spironolactone was associated with 60{\%} reduction of new AF (HR = 0.372 [0.200-0.692], P = 0.002) and the protective effect is dose-responsive in accumulated dose, treatment duration and mean daily dose. After PS matching, the overall AF prevention effect remained significant (HR = 0.400 [0.179-0.895], P = 0.026) while the dose-response relationship became borderline significant. Subgroup analyses showed that the protective effect was more evident in some specific subgroup patients. Conclusion: Our study showed that spironolactone therapy was associated with lower risk of developing AF in a dose-responsive manner in patients with dialysis. Further randomized study is needed to confirm this observation.",
keywords = "Atrial fibrillation, ESRD, Hemodialysis, Spironolactone, Atrial fibrillation, ESRD, Hemodialysis, Spironolactone",
author = "Chung, {Yi Wei} and Yang, {Yao Hsu} and Wu, {Cho Kai} and Yu, {Chih Chieh} and Juang, {Jyh Ming Jimmy} and Wang, {Yi Chih} and Tsai, {Chia Ti} and Lin, {Lian Yu} and Lai, {Ling Ping} and Hwang, {Juey Jen} and Chiang, {Fu Tien} and Chen, {Pau Chung} and Lin, {Jiunn Lee}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2015.05.167",
language = "English",
volume = "202",
pages = "962--966",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy

AU - Chung, Yi Wei

AU - Yang, Yao Hsu

AU - Wu, Cho Kai

AU - Yu, Chih Chieh

AU - Juang, Jyh Ming Jimmy

AU - Wang, Yi Chih

AU - Tsai, Chia Ti

AU - Lin, Lian Yu

AU - Lai, Ling Ping

AU - Hwang, Juey Jen

AU - Chiang, Fu Tien

AU - Chen, Pau Chung

AU - Lin, Jiunn Lee

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear. Methods: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute. All dialysis patients aged 18 or older without history of AF before ESRD were incorporated. A total of 113,191 dialysis patients were enrolled in the study. The median follow-up time was 4.17 years. We collected information on prescribed drug dosage, number of days of treatment and the total number of pills dispensed from the outpatient pharmacy prescription database. All individuals in the study cohort with the first occurrence of AF were included as cases. Results: In spironolactone group, the incidence of developing new AF was significantly lower than that in the control group both before (0.8% vs. 3.3%, P = 0.019) and after PS matching (1.2% vs. 3.0%, P = 0.019). Before PS matching, Cox's proportional hazard regression analyses showed that spironolactone was associated with 60% reduction of new AF (HR = 0.372 [0.200-0.692], P = 0.002) and the protective effect is dose-responsive in accumulated dose, treatment duration and mean daily dose. After PS matching, the overall AF prevention effect remained significant (HR = 0.400 [0.179-0.895], P = 0.026) while the dose-response relationship became borderline significant. Subgroup analyses showed that the protective effect was more evident in some specific subgroup patients. Conclusion: Our study showed that spironolactone therapy was associated with lower risk of developing AF in a dose-responsive manner in patients with dialysis. Further randomized study is needed to confirm this observation.

AB - Objectives: Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear. Methods: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute. All dialysis patients aged 18 or older without history of AF before ESRD were incorporated. A total of 113,191 dialysis patients were enrolled in the study. The median follow-up time was 4.17 years. We collected information on prescribed drug dosage, number of days of treatment and the total number of pills dispensed from the outpatient pharmacy prescription database. All individuals in the study cohort with the first occurrence of AF were included as cases. Results: In spironolactone group, the incidence of developing new AF was significantly lower than that in the control group both before (0.8% vs. 3.3%, P = 0.019) and after PS matching (1.2% vs. 3.0%, P = 0.019). Before PS matching, Cox's proportional hazard regression analyses showed that spironolactone was associated with 60% reduction of new AF (HR = 0.372 [0.200-0.692], P = 0.002) and the protective effect is dose-responsive in accumulated dose, treatment duration and mean daily dose. After PS matching, the overall AF prevention effect remained significant (HR = 0.400 [0.179-0.895], P = 0.026) while the dose-response relationship became borderline significant. Subgroup analyses showed that the protective effect was more evident in some specific subgroup patients. Conclusion: Our study showed that spironolactone therapy was associated with lower risk of developing AF in a dose-responsive manner in patients with dialysis. Further randomized study is needed to confirm this observation.

KW - Atrial fibrillation

KW - ESRD

KW - Hemodialysis

KW - Spironolactone

KW - Atrial fibrillation

KW - ESRD

KW - Hemodialysis

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=84959859505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959859505&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.05.167

DO - 10.1016/j.ijcard.2015.05.167

M3 - Article

C2 - 26323866

AN - SCOPUS:84959859505

VL - 202

SP - 962

EP - 966

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -